Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986165 in Healthy Subjects and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of BMS-986165 in Subjects With Moderate to Severe Psoriasis

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986165 in Healthy Subjects and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of BMS-986165 in Subjects With Moderate to Severe Psoriasis

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs BMS 986165 (Primary) ; Famotidine; Interferon alpha-2a; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Adverse reactions; First in man
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 17 Jun 2017 Results assessing safety, pharmacokinetics, and pharmacodynamics of BMS-986165 in healthy volunteers (n=108), presented at the 18th Annual Congress of the European League Against Rheumatism
    • 14 Jun 2017 According to a Bristol-Myers Squibb media release, data will be presented at the Annual European Congress of Rheumatology (EULAR 2017)
    • 02 Dec 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top